Semaglutide clinical trials, in English

Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

NCT03884075 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

NCT05819853 · Official ClinicalTrials.gov record · University of Colorado, Denver

TITLE: How GLP-1 Analogues prevent steroid-induced diabetes (The GAPSID Study) DESIGN: A neither you nor the study doctors know who gets the real treatment study evaluating how GLP-1 analogues, compared with metformin, prevent hyperglycaemia in response to a 7-day course of dexamethasone (DEX) 6 mg once daily. This is a mechanistic experimental medicine study.

NCT06318442 · Official ClinicalTrials.gov record · Imperial College London

The is a pilot, 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, randomly assigned trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching dummy treatment (placebo) (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD.

NCT06639464 · Official ClinicalTrials.gov record · Brigham and Women's Hospital

This study wants to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with dummy treatment (placebo) in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

NCT06897475 · Official ClinicalTrials.gov record · Eli Lilly and Company

What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms?

NCT06975111 · Official ClinicalTrials.gov record · University of Colorado, Denver

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1.

NCT07107334 · Official ClinicalTrials.gov record · University of Florida

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.

NCT07207148 · Official ClinicalTrials.gov record · Northwestern University

The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or dummy treatment (placebo), and in the second part participant will get CagriSema.

NCT07282613 · Official ClinicalTrials.gov record · Novo Nordisk A/S

This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression. NAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome.

NCT07391267 · Official ClinicalTrials.gov record · Institute of Liver and Biliary Sciences, India

The goal of this clinical trial is to assess whether added on top of your current treatment dental cleaning can enhance the effects of semaglutide in children with obesity. The main question\[s\] it aims to answer \[is/are\]: if dental cleaning will improve both oral health and metabolic outcomes beyond the effects of semaglutide alone.

NCT07478653 · Official ClinicalTrials.gov record · Oelisoa Andriankaja

The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: * Will excessive fat be associated with brain abnormalities on MRI measures?

NCT07592546 · Official ClinicalTrials.gov record · Alain Dagher

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.

NCT07651319 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute

This study wants to measure the how well it works, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

NCT07662213 · Official ClinicalTrials.gov record · AstraZeneca

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes.

NCT07668388 · Official ClinicalTrials.gov record · Novo Nordisk A/S

The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, how well it works and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.

NCT07743983 · Official ClinicalTrials.gov record · BrightGene Bio-Medical Technology Co., Ltd.

This study is a 6-month, two-arm, RCT which will measure the effectiveness and safety of semaglutide in adolescents aged 12-18 years with autism spectrum disorder (ASD) and obesity. The primary outcome is change in body mass index (body-mass index (BMI), kg/m²) from baseline to Month 6.

NCT07770152 · Official ClinicalTrials.gov record · Children's Hospital Medical Center, Cincinnati

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus dummy treatment (placebo) in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

NCT07772960 · Official ClinicalTrials.gov record · Yale University

Use these resources to provide understandable information about this study to patients, families, and health care providers:

NCT07840729 · Official ClinicalTrials.gov record · Shanghai JMT-Bio Inc.

This study wants to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.

NCT07845500 · Official ClinicalTrials.gov record · Pfizer

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

NCT07855133 · Official ClinicalTrials.gov record · Novo Nordisk A/S

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity.

NCT07858864 · Official ClinicalTrials.gov record · Istanbul Saglik Bilimleri University

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

NCT07866066 · Official ClinicalTrials.gov record · Amgen

The goal of this clinical trial is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy®), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis. The main question it aims to answer is: to identify for whom semaglutide works best.

NCT07870538 · Official ClinicalTrials.gov record · Universitaire Ziekenhuizen KU Leuven

The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor mental health, and decreased life expectancy.

NCT07872904 · Official ClinicalTrials.gov record · Signe Torekov

The goal of this 24 week double-blinded, randomly assigned, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity. The main question to answer is: What effect does Semaglutide have on body composition in adults with type 1 diabetes and overweight/obesity compared to a dummy treatment (placebo)?

NCT07891156 · Official ClinicalTrials.gov record · McGill University Health Centre/Research Institute of the McGill University Health Centre

The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes. The main questions it aims to answer are: \- Does tirzepatide have a greater effect on energy expenditure or energy extraction than semaglutide?

NCT07900074 · Official ClinicalTrials.gov record · McMaster University

The purpose of this clinical study is to find out what happens to kidney and heart health during treatment with a medicine called semaglutide, which is given as an injection under the skin. The clinical study will also look at whether this medicine is safe for adults who have type 2 diabetes (T2D) and chronic kidney disease (CKD).

NCT07900438 · Official ClinicalTrials.gov record · Novo Nordisk A/S

This prospective watch-and-measure (no experimental treatment required) study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.

NCT07924618 · Official ClinicalTrials.gov record · Istanbul University

The goal of this watch-and-measure (no experimental treatment required) study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity. The main questions this study aims to answer are: * What is the composition of weight loss during incretin treatment?

NCT07929831 · Official ClinicalTrials.gov record · Radboud University Medical Center